Recombinant DNA technology and its applications

Shuvam Purkait

PhD Scholar

Center for the environment.

Indian Institute of Technology Guwahati.

City: Guwahati

Email: s.purkait@iitg.ac.in

Parvaiz Yousuf\*

Department of Zoology,

Central University of Kashmir,

Ganderbal (191201)

J&K, India

Email: saleemparvaiz444@gmail.com

Phone: +91-7889474790

**Abstract**

Recombinant DNA technology is a powerful method for manipulating genetic information to produce valuable products with enhanced traits. This review paper provides an overview of its principles and recent advances in various sectors. The paper introduces recombinant DNA technology, involving restriction endonucleases and DNA ligase enzymes to insert desired DNA fragments into vectors. It traces its historical development and highlights advancements since the mid-1980s, leading to various products for better health. Recent advances in gene therapy are explored, with successful outcomes in treating genetic diseases, cancer, and cardiovascular disorders through gene transfer targeting hematopoietic stem cells. The CRISPR-Cas system's emergence and diverse applications in gene targeting and editing are discussed. The application in the health sector is further explored, with a focus on antibody production, drug metabolism investigation, vaccines, and recombinant hormones. In environmental sciences, bioremediation using genetically modified bacteria is highlighted, as well as enhanced hydrogen production in cyanobacteria for clean energy. The role in the agricultural sector is examined, emphasizing the production of specialized enzymes and microbial strains for food processing, improving food safety and preservation. The book chapter showcases the transformative potential of recombinant DNA technology in genetics, medicine, agriculture, and environmental sciences, offering solutions to pressing global challenges.

**Keywords:** Recombinant DNA technology; Gene therapy; CRISPR-Cas system; Bioremediation; Agricultural applications

1. **Introduction**

Recombinant DNA technology has emerged as a powerful method in the field of genetics and molecular biology, revolutionizing scientific research, medical advancements, and the development of novel products [1]. This technique involves the manipulation of genetic information outside of an organism to produce valuable products with enhanced desired traits. By inserting specific gene sequences from various sources into convenient vectors, scientists can modify the genetic material of an organism to introduce novel genes, alter gene expression levels, or combine existing genes and components to create structurally identical compounds for various applications. The inception of recombinant DNA molecules can be traced back to the landmark achievement in 1973 when Paul Berg, Annie Chang, Herbert Boyer, and Stanley Cohen successfully produced the first recombinant DNA (rDNA) molecules. Subsequent discussions at the 1975 "Asilomar Conference" highlighted the management and safety implications of rDNA technology. However, initial expectations for swift applications in agriculture and pharmaceuticals were faced with unforeseen challenges, delaying the realization of positive outcomes. Nevertheless, since the mid-1980s, significant advancements have been made in this field, leading to the creation of a wide array of products for better health, including hormones, vaccines, therapeutic agents, and diagnostic tools [2,3]. Recombinant DNA technology has enabled rapid investigations of genetic expressions and mutations in eukaryotic genes. Examples include cloned insulin genes inserted into a simian virus fragment to examine genetic expressions related to mutations. Moreover, the use of adenoviral vectors carrying endostatin in its human secretory form has demonstrated antiangiogenic properties that reduce tumor proliferation. Additionally, targeted gene disruption has facilitated the creation of structurally identical anticancer compound manufacturing pathways in various hosts.

The development of longer-acting medicinal proteins has been made possible through recombinant DNA technology, involving the incorporation of sequences with additional glycosylation sites. This has led to the creation of novel chimeric genes with enhanced therapeutic properties. The combination of vectors for gene therapy and genetic alteration, particularly viral vectors, has garnered significant attention in the medical field, with some already commercialized. However, advancements have also led to the production of therapeutic-grade viral vectors [9]. Despite the decline in popularity of retroviral vectors due to their adverse effects, alternative approaches, such as direct administration of "naked" genetic material into specific tissues, have shown promising results. Recent advances in recombinant DNA technology include the development of innovative cloning technologies like the P1 vector for electroporating recombinant DNA into E. coli, allowing the creation of large clone libraries. Additionally, lower copy number vectors such as pWSK29, pWSK129, pWKS30, and pWKS130 have been employed in DNA sequencing, complementation analysis, and unidirectional deletions. In this book chapter, we explore the recent advances in recombinant DNA technology, focusing on its applications in the health sector. Gene therapy has emerged as a cutting-edge therapeutic approach, showing great promise in the treatment of genetic diseases, cancer, and cardiovascular disorders. We delve into the successes and challenges of gene therapy and its potential to revolutionize healthcare [12]. Moreover, we discuss the production of antibodies and their derivatives using recombinant DNA technology, offering novel approaches in disease diagnosis and treatment. Furthermore, we explore the application of recombinant DNA technology in investigating drug metabolism, the development of vaccines and recombinant hormones, and its role in traditional Chinese medicines. Finally, we examine how genetic engineering has opened new possibilities for addressing environmental challenges, such as bioremediation and energy applications. Overall, this book chapter provides an overview of the significant advancements in recombinant DNA technology and its potential to transform various industries and improve human well-being. The continuous progress in this field holds promising prospects for innovative scientific research and medical breakthroughs, offering hope for a healthier and sustainable future.

1. **Understanding Recombinant DNA Technology**

Recombinant DNA technology is a powerful method that involves the manipulation of genetic information outside of an organism to produce valuable products with enhanced desired traits. By utilizing convenient vectors, this technique allows the insertion of desired DNA fragments from various sources, containing specific gene sequences **(Figure 1.)** [1]. The genetic material of an organism can be modified either by introducing novel genes and regulatory components or by recombining existing genes and components to regulate the expression levels of endogenous genes [2]. The process of recombinant DNA technology involves the use of restriction endonucleases to enzymatically cleave DNA into various fragments of interest **(Table 1.)**. These fragments are then joined together using DNA ligase enzymes to insert the desired gene into the vector. The host organism is then treated with the vector containing the gene of interest, and the integrated DNA fragment is propagated throughout the culture to generate clones harboring the specific DNA segment [3]. The inception of recombinant DNA molecules can be traced back to 1973 when Paul Berg, Annie Chang, Herbert Boyer, and Stanley Cohen of Stanford University and University of California San Francisco successfully produced the first recombinant DNA (rDNA) molecules. Subsequently, the management and safety implications of rDNA technology were discussed during the 1975 "Asilomar Conference." However, despite initial expectations, the application of recombinant DNA techniques in agriculture and pharmaceuticals faced unforeseen challenges and impediments, delaying the realization of positive outcomes. Nevertheless, significant advancements have been made since the mid-1980s, resulting in the creation of a wide array of products for better health, including hormones, vaccines, therapeutic agents, and diagnostic tools [2].

Recombinant DNA technology has been instrumental in rapidly investigating the genetic expression of mutations introduced in eukaryotic genes. For example, cloned insulin genes were inserted into a simian virus fragment, allowing for the examination of genetic expression related to these mutations [4]. Similarly, the use of adenoviral vectors carrying endostatin in its human secretory form has demonstrated antiangiogenic properties that reduce tumor proliferation. The efficacy of antiangiogenesis is further enhanced by the restoration of Ad-Endo replication through dl1520 [5]. Targeted gene disruption has facilitated the creation of structurally identical anticancer compound manufacturing pathways in various hosts [6]. Additionally, longer-acting medicinal proteins have been developed using recombinant DNA technology, with a common approach involving the use of sequences with additional glycosylation sites. This method led to the creation of a novel chimeric gene incorporating the hCG β-subunit C-terminal peptide and the FSH β-subunit coding sequences [7]. Researchers have also developed and combined vectors for gene therapy and genetic alteration. Viral vectors, in particular, have gained significant attention in the medical field and some have even been commercialized. These modified viruses serve various purposes, including cancer treatment through ex vivo gene therapy or in vivo protein transduction techniques and vaccinations [8]. Notably, improvements in manufacturing techniques have enabled the production of therapeutic-grade viral vectors [9]. However, retroviral vectors have somewhat declined in popularity due to their serious adverse effects, despite their efficient and precise gene transfer capabilities in a variety of animals. An alternative approach involves the direct administration of "naked" genetic material into specific tissues, particularly muscles, resulting in significant gene expression with minimal adverse effects [10].

Recent advancements have also led to the successful development of the P1 vector for electroporating recombinant DNA into E. coli using electroporation procedures. This innovative cloning technology allows the creation of a 15,000-clone library with an initial average insert size of 130–150 kb pairs. One of the most prominent applications of the PAC cloning technology is in complex genome analysis and mapping [11]. Additionally, PCR and recombinant DNA techniques have been employed to create lower copy number vectors, such as pWSK29, pWSK129, pWKS30, and pWKS130. These vectors find application in DNA sequencing, run-off transcription, complementation analysis, and unidirectional deletions [12]. Thus, recombinant DNA technology has revolutionized the field of genetics and molecular biology, offering numerous opportunities for scientific research, medical advancements, and the development of novel products. As scientists continue to refine and expand this technology, it is poised to play a central role in shaping the future of various industries and improving human well-being.



**Figure 1.** Mode of action of Recombinant DNA Technology.

**Table 1.** Different Restriction Endonucleases with their source show their unique digestion site. Only one strand of double-stranded DNA shows in the sequence. “N” represents any base.

|  |  |  |
| --- | --- | --- |
| Enzymes | Site for restriction digestion | Origin |
| *Eco*RI | GAATTC |  *Escherichia coli* RY13 |
| *Hin*dIII | AAGCTT |  *Haemophilus influenzae* Rd |
| *Bam*HI | GGATCC | *Bacillus amyloliquefaciens* H |
| *Hae*III | GGCC |  *Haemophilus aegyptius* |
| *Mbo*I | GATC | *Moraxella bovis* |
| *Hpa*II | CCGG | *Haemophilus parainfluenzae* |
| *Hpa*I | GTTAAC | *Haemophilus parainfluenzae* |
| *Sfi*I | GGCCNNNNNGGCC | *Streptomyces fimbriatus* |
| *Not*I | GCGGCCGC | *Nocardia otitidis-caviarum* |
| *Taq*I | TCGA | *Thermus aquaticus* |

1. **Recent Advances in Recombinant DNA Technology**

Recombinant DNA technology has become a rapidly expanding area of research, with scientists worldwide developing novel techniques, tools, and modified products for various applications in health, agriculture, and the environment. Notably, Lispro (Humalog), a highly efficient and fast-acting recombinant insulin, has demonstrated superiority over conventional human insulin [4]. Similarly, Epoetin alfa, a newly introduced recombinant protein, has found widespread use in the effective treatment of anemia [13]. Another significant advancement is the recombinant hGH, which has proven highly effective in treating growth hormone deficiency in children [14]. Furthermore, the approval of clinical trials for a recombinant form of the cytokine myeloid progenitor inhibitory factor-1 (MPIF-1) by the FDA showcases the potential of this technology in mitigating the negative effects of anticancer medications [15]. A major breakthrough in recombinant DNA technology is the clustered regularly interspaced short palindromic repeats (CRISPR) system, which has provided solutions to various challenges in different organisms. CRISPR allows gene targeting and editing in human cells, mice, zebrafish, rats, fruit flies, yeast, bacteria, nematodes, and crops, significantly advancing research on human diseases and gene interactions [16]. The CRISPR system in *H. hispanica* efficiently adapts to nonlytic viruses, and the related Cas operon encodes interacting Cas3 nucleases and additional Cas proteins for adaptive immunity [17]. Through a photo-spacer integration, the CRISPR system saves information about invading genetic material [18]. Moreover, Cas9t gene editing tool employs RNA molecules for sequence-specific recognition of specific targets [19], while Class 2 CRISPR-Cas systems with a single protein effector, such as dead Cas9, have been used for various applications, including recruitment of histone modifying enzymes, fluorescent protein labeling, transcriptional regulation, and more [20]. By targeting specific genes and employing natural CRISPR-cas immunity, strains can be developed to resist various harmful viruses [21].

The CRISPR-Cas system, with its adaptable immune system found in prokaryotes, relies on the Cas genes encoding Cas proteins, including Cas1 and Cas2 in Escherichia coli, which facilitate the formation of new spacers [22]. The process of interference and acquisition requires a photo-spacer adjacent motif (PAM), and the CRISPR array's transcription into precursor crRNA initiates the memorizing of the invader's sequence. The immune process weakens the target in its final stages due to interference by invasion nucleic acids, while specific recognition prevents self-targeting [23]. In Sulfolobus species, CRISPR loci with numerous spacers closely resembling conjugative plasmids suggest an influence of active viral DNA replication on spacer acquisition, with DNA break generation at replication forks stimulating the process [24]. Considering the significant contributions of the CRISPR-Cas system to maintaining stability and improving immunity, it has become an indispensable component of complex biological systems. Besides CRISPR, chimeric nucleases like zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) have been developed, offering more target-specific therapeutic efficacy [25]. Furthermore, recombinant proteins like fibroblast growth factor (FGF-1) have been created to promote the formation of new blood vessels in the myocardium, significantly enhancing blood flow and serving as potential treatments for leg ulcers and diabetic ulcers [26]. In addition to insulin, recombinant DNA technology has enabled the synthesis of numerous new medications, and efforts are underway to improve manufacturing pipelines for various drugs and vaccines [27].

However, challenges persist in the development of molecular medicine based on proteins, with the need to increase the quantity and quality of molecular-based medicines. Cell factories are considered crucial for recombinant DNA technologies, but their limitations must be addressed to meet the increasing demands [27]. The creation of oncolytic adenovirus using endothelial growth factor and Notch signaling holds promise as an anticancer drug, disrupting tumor angiogenesis and enhancing overall vascular effects [2]. Additionally, efforts to alter the influenza virus genome through recombinant DNA technology to create vaccinations have shown promise [6]. To optimize the manufacturing of recombinant proteins, advancements in cell physiology and environmental control are necessary. Microorganisms are considered convenient hosts for molecular drug production due to their less resistant barriers for assimilating foreign genes and ease of expression regulation. Microbial systems offer simpler apparatus compared to plant and animal cells, leading to improved performance and quality of protein production. Widespread microbial species like yeasts and bacteria have demonstrated promise as cellular factories for recombinant molecular medicine, and less common strains also hold potential in this regard [28].

1. **Application of Recombinant DNA technology in Health Sector**

Recombinant DNA technology has demonstrated a diverse array of applications in the treatment of diseases and the improvement of human well-being. The sections below outline the noteworthy progress made in this field, which has the potential to significantly enhance human health.

 ***4.1. Gene Therapy:***

Gene therapy is an emerging and cutting-edge therapeutic approach in healthcare, showing great promise in the treatment of various genetic diseases, cancer, and cardiovascular disorders. The landmark success in gene therapy was demonstrated in the treatment of a genetic disease, specifically primary immunodeficiency adenosine deaminase-deficiency (ADA-SCID) [29]. However, initial inefficiencies and challenges were encountered, such as the necessity to maintain patients on PEGylated ADA (PEG-ADA) throughout gene therapy and the need to target gene transfer to T-lymphocytes [30]. Nevertheless, advancements in gene transfer methodologies, particularly targeting haematopoietic stem cells (HSCs) with a myeloablative conditioning regimen, have led to successful outcomes in gene therapy [31]. Furthermore, gene therapy has shown great potential in treating other genetic diseases like X-linked adrenoleukodystrophy (X-ALD) [32]. The use of lentiviral vectors based on HIV-1 allowed the successful modification of HSCs' genes, leading to the cure of hereditary human illness for the first time [32]. In addition, gene therapy has paved the way for novel treatment approaches in the field of immunotherapy, exemplified by its use in metastatic melanoma [33]. Through the use of a retrovirus encoding a T-cell receptor, patients exhibited a regression of metastatic melanoma lesions after infusion [33]. Moreover, in treating chronic lymphocytic leukaemia, genetically altered autologous T-cells expressing chimeric antigen receptors (CAR) with specificity for the B-cell antigen CD19 have shown promising results [34]. This approach has also demonstrated selective expansion in genetically edited cells for disorders such as SCID-X1 and ADA-SCID due to in vivo selection facilitated by the disease pathogenesis [34].

The progress in gene therapy is not limited to genetic diseases, as it has also shown significant advancements in cancer treatment. Gene therapy has been utilized to treat a wide range of cancers, including haematological malignancies, paediatric tumours, lung, gynaecological, cutaneous, urological, neurological, and gastrointestinal tumours [10]. Various approaches have been employed, such as the insertion of tumour suppressor genes into immunotherapy, oncolytic virotherapy, and gene-directed enzyme prodrug treatment [10]. The tumour suppressor gene p53, frequently inherited, plays a pivotal role in cancer gene therapy and is often combined with radiotherapy or chemotherapy to enhance treatment efficacy [10]. Additionally, vaccination using tumour cells engineered to produce immunostimulatory molecules, recombinant viral vectors encoding tumour antigens, and host cells expressing tumour antigens are prominent approaches currently being explored [10]. The use of Ad5/35-EGFP, a novel fibre chimeric oncolytic adenovirus vector, has shown potential as an effective anticancer agent, especially in the treatment of hepatocellular carcinoma [37]. In cardiovascular medicine, gene therapy presents exciting opportunities for therapeutic angiogenesis, myocardial protection, regeneration, repair, and preventing restenosis after angioplasty and bypass graft collapse [38]. Inherited immunodeficiency disorders like Wiskott-Aldrich Syndrome can be treated using ex vivo gene therapy when matched donors for stem cell transplantation are unavailable [38]. Furthermore, immunotherapy utilizing gene-engineered T-cells has shown promise in the retreatment of metastatic cancer [38]. The success of this approach lies in accurate selection of antigens expressed by tumours and reprogramming T-cells to resist immunosuppression before reintroducing them into the patient [38]. The microenvironment of cancer cells frequently suppresses T-cell survival and migration, making them almost "invisible" to the immune system. Genetic engineering of T-cells can address these challenges, resulting in altered T-cells that can recognize cancer-specific antigens, resist immunosuppression, extend longevity, and aid migration to tumours [38]. Additionally, the use of the CRISPR/Cas9 system has shown potential in conferring susceptibility to anaplastic lymphoma kinase (ALK) inhibitors by introducing specific chromosomal alterations [39].

Another promising therapeutic strategy in cancer treatment is targeting the Wnt system. LGK974, a potent inhibitor of Wnt signalling, has shown good safety and efficacy in rodent tumour models. It has exhibited high levels of response in head and neck cancer cell lines with loss-of-function mutations affecting the Notch signalling system [40]. Additionally, viral gene therapy targeting tumor-associated genes, such as p53, has shown effectiveness in treating head and neck cancers. Oncolytic virus strains have been utilized to eliminate cancer cells by replicating virally and equipping themselves with therapeutic transgenes. Furthermore, gene knockouts have improved the ability of cells to develop into macrophages and specifically target desired pathogens. These gene knockouts enable the study of protein coding alterations and regulatory variations in macrophages, simplifying the understanding of mRNA transcription and stability [42]. Thus, gene therapy has emerged as a cutting-edge and promising approach in healthcare, offering potential cures for severe genetic diseases and significant advancements in cancer and cardiovascular treatments. The success of gene therapy in specific genetic diseases, such as ADA-SCID and X-ALD, underscores the therapeutic potential of this approach [29-30]. Gene therapy has also demonstrated remarkable progress in cancer treatment, employing various approaches to target different forms of cancer, and holds promising possibilities for cardiovascular medicine [10, 38]. Future research and advancements in gene editing technologies like CRISPR/Cas9 will likely enhance the efficacy and applicability of gene therapy in various medical disciplines [32, 39]. While challenges remain, continuous progress in viral vector design and gene engineering techniques holds promise for the future of gene therapy, offering novel and effective treatments for a wide range of diseases.

***4.2. Production of Antibodies and Their Derivatives:***

Recently, significant progress has been made in developing and expressing antibodies and their derivatives in plant systems. Notably, seven antibodies and antibody derivatives have successfully advanced to required stages. For instance, chimeric secretory IgA/G, also known as CaroRx, has been produced from transgenic tobacco plants. CaroRx has the ability to identify Streptococcus variants, an oral pathogen responsible for tooth decay [43]. Additionally, the monoclonal antibody T84.66 has shown functional recognition of the antigen carcinoembryonic, a well-characterized biomarker in epithelial malignancies [43]. In transgenic soybean and Chinese Hamster Ovary (CHO) cells, a full-length humanized IgG1 antibody referred to as anti-HSV and anti-RSV has been expressed. This antibody serves as the recognizing agent for herpes simplex virus (HSV)-2-glycoprotein B. Topical application of these antibodies in mice has demonstrated the potential to prevent the transmission of HSV-2 through the vagina [44]. If the same effect is observed in humans, this approach could offer a practical and affordable method of preventing infections resulting from sexual contact.

Another antibody of interest is the scFv antibody 38C13, which is based on the malignant B lymphocyte idiotype found in the well-studied mouse lymphoma cell line 38C13. Treatment with this antibody in mice has led to the development of anti-idiotype antibodies capable of identifying 38C13 cells and providing protection against deadly challenges of injected lymphoma cells [45]. This approach holds promise for developing distinct indicators recognizing enzymes, particularly surface markers of malignant B-cells, and could serve as an effective treatment for non-Hodgkin lymphoma-like disorders in humans. The specific recognition of human chorionic gonadotropin is achieved by a monoclonal antibody known as PIPP. By utilizing transgenesis and agroinfiltration in transiently transformed tobacco, full-length monoclonal antibodies, scFv, and diabody derivatives have been successfully manufactured in plants [46]. In cells cultivated by LEYDIG, stimulated hCG can suppress the generation of testosterone, and in mice used to measure hCG activity, an increase in uterine weight can be slowed. These advancements in expressing antibodies and their derivatives in plant systems offer promising applications in the diagnosis and treatment of tumors and other diseases [43-46]. Utilizing plants as biofactories for antibody production could potentially lead to more accessible and cost-effective treatment options in the future. However, further research and clinical trials are required to fully understand the effectiveness and safety of these novel approaches in human therapeutics.

***4.3. Investigation of the Drug Metabolism:***

Recent advances in recombinant DNA techniques have enabled the examination of enzyme systems that regulate drug metabolism through heterologous expression, allowing for the production of genetic material in vitro or in vivo by gene transfer [47]. This approach is essential for optimizing therapeutic efficacy and effects in healthcare.

***4.4. Development of Vaccines and Recombinant Hormones:***

Recombinant vaccines offer greater efficacy and specificity compared to traditional vaccines. A rapid and efficient method for safeguarding against mucosal diseases is nasal transfer, using adenovirus vectors encoding pathogen antigens. This painless approach results in the expression of the transgene in the airway, creating a pharmacological vaccination and inducing an anti-influenza state [48]. With the aid of recombinant DNA technology, human follicle-stimulating hormone (FSH) can now be produced in vitro. This highly complex heterodimeric protein is expressed in a specific eukaryotic cell line. In assisted reproductive therapy, this advancement has successfully stimulated follicular development, and recombinant FSH (r-FSH) is widely used in treating numerous individuals. Additionally, the successful recombination of r-FSH and luteinizing hormone (LH) has proven to be a compelling development, promoting ovulation and pregnancy [49].

***4.5. Chinese Medicines:***

Traditional Chinese Medicines (TCMs) play a crucial role in alternative medicine, providing valuable insights for both diagnostics and treatments. Interestingly, some of these medicines align with the principles of gene therapy, suggesting potential applications as co-administered medications and sources of therapeutic genes. The transgenic root system, in conjunction with the Ri plasmid, holds promise for introducing additional genes. A. rhizogenes vector systems are employed to carry modified genes, enhancing specific properties for particular purposes. These cultures have become invaluable tools for investigating the biochemical characteristics and gene expression patterns of metabolic pathways. By utilizing transformed cultures, researchers can gain insights into the intermediates and essential enzymes involved in the synthesis of secondary metabolites [50].

***4.6. Medically Important Compounds in Berries:***

The incorporation of the rolC gene has significantly improved the nutritional value of strawberries by increasing both sugar content and antioxidant activity. To enhance various components of strawberries, including anthocyanins, proanthocyanidin, l-ascorbate, flavonoids, and polyphenols, genetic modification requires the involvement of key enzymes such as transferase and glycosyl-transferase. Similarly, in the case of raspberries, the bHLH and FRUITE4 genes regulate anthocyanin components, while ERubLRSQ072H02 is associated with flavonol production. These genes hold the potential to boost production and elevate the quality of strawberries and raspberries through precise genetic transformation, ultimately yielding various health benefits due to the presence of medicinal compounds [51].

1. **Recombinant DNA Technology in Environmental Science**

Genetic engineering offers promising solutions to various environmental issues. Collaborative efforts between the University of Tennessee and Oak Ridge National Laboratory have led to groundbreaking advancements in bioremediation using genetically modified bacteria, such as the Pseudomonas fluorescens strain HK44. This strain contains the plasmid pUTK21, which facilitates the breakdown of naphtha, thereby enhancing naphthalene degradation [52]. Moreover, the incorporation of a transposon-based bioluminescence-producing lux gene with a promoter has resulted in a heightened bioluminescent response during naphthalene breakdown, turning HK44 into a valuable tool for monitoring bioremediation processes in real-time due to its bioluminescence signaling capacity [53]. By using fibre optics and photon counting modules, the presence of the bioluminescent signal can be accurately detected [52]. The successful utilization of genetically engineered bacteria for bioremediation purposes opens new avenues for addressing environmental challenges effectively and sustainably.

* 1. ***Phytoremediation and Plant Resistance Development:***

Genetic engineering has proven to be an effective approach in the detection and absorption of pollutants in drinking water and other environmental specimens. For instance, the introduction of the AtPHR1 gene into plants such as Verbena, Torenia, and Petunia has significantly altered their capacity to absorb Pi, thereby improving phytoremediation in contaminated aquatic environments [54]. The AtPHR1 gene was incorporated into the binary vector pBinPLUS with an enhanced cauliflower mosaic virus 35S promoter, and Agrobacterium tumefaciens was used to transform Petunia and Verbena with the plasmid pSPB1898 [55]. However, overexpressing AtPHR1 may hinder the posttranscriptional modification of the endogenous AtPHR1 homologue [54, 103].

Plant metabolism plays a crucial role in utilizing plants to remove toxins from the environment. Some pollutants are not easily digested or broken down by plants. For instance, TNT undergoes only partial digestion, leading to the production of lethal superoxide when nitrogen interacts with oxygen. To address this issue, the knockout of the monodehydroascorbate reductase gene increases the plant's tolerance to TNT. Similarly, fine-tuning enzyme activity through knockout engineering enhances plant responses to hazardous metals. For instance, attenuating the enzymatic activity of the heavy metal binding peptide synthesis enzyme phytochelatin synthase improves tolerance to heavy metals [56].

Recombinant DNA technology has also demonstrated efficacy in eliminating soil pollutants, such as arsenic, which is a major concern. Arabidopsis expressing the PvACR3 gene, a crucial arsenite [As(III)] antiporter, exhibited increased arsenic tolerance. Unlike wild-type seeds, genetically altered seeds with PvACR3 can germinate and flourish under conditions of elevated arsenate [As(V)] concentrations [57]. Additionally, the enzyme reductase found in A. thaliana reduces arsenic (As), and phytochelatins restrict the migration of arsenic in phloem companion cells and root cells.

Various biotechnology techniques for bioremediation, such as biosorption, phytostabilization, mycoremediation, hyperaccumulation, dendroremediation, biostimulation, cyanoremediation, and genoremediation, primarily rely on boosting or blocking specific gene activity. However, implementing an effective strategy for bioremediation poses significant challenges [59]. The application of genetic engineering in bioremediation opens new possibilities for addressing environmental pollution and promoting sustainable remediation processes.

* 1. ***Energy Applications:***

Microbes, particularly cyanobacteria, offer a promising avenue for producing eco-friendly hydrogen as an energy source. Through the appropriate utilization of essential enzymes crucial for hydrogen production, cutting-edge techniques such as metabolic engineering, cell-free technology, mixed culture, genetic engineering, and changes in food and growth conditions have shown potential for enhancing hydrogen production in cyanobacteria [60]. The commercialization of hydrogen as an energy source is vital for maintaining a clean environment, as conventional energy sources release CO2 and other harmful compounds. Moreover, modifying cyanobacteria to convert CO2 into reduced fuel components can further reduce the environmental impact of carbon-based energy sources, particularly for industrial compounds like short- and medium-chain alcohols [61].

*Geobacter sulfurreducens* conductive biofilms present exciting prospects for bioelectronics, bioremediation, and renewable energy. Deletion of the PilZ genes in the *G. sulfurreducens* genome resulted in a more active biofilm than the wild type. Additionally, deletion of the gene GSU1240 (CL-1ln) improved biofilm generation, pili, and exopolysaccharide synthesis. When these biofilms were cultivated with an electrode, the electron acceptor CL-1 produced biofilms that exhibited six times higher conductivity than the wild-type. The increased conductivity significantly reduced potential losses in microbial fuel cells by lowering the formal potential and reducing the charge transfer barrier at the biofilm-anode surface, resulting in an increase in potential energy [62].

Plant metabolism plays a significant role in the removal of toxins from the environment. However, many compounds are not easily digested or broken down. For instance, TNT undergoes partial digestion, leading to the production of lethal superoxide when nitrogen interacts with oxygen. Knocking out the monodehydroascorbate reductase gene can increase the plant's tolerance to TNT. Additionally, genetic engineering and fine-tuning enzyme activity can enhance plant responses to hazardous metals. By attenuating enzymatic activity, the heavy metal binding peptide synthesis enzyme phytochelatin synthase can improve tolerance to heavy metals [56]. Recombinant DNA technology has shown efficacy in eliminating soil pollutants, such as arsenic. Arabidopsis expressing the PvACR3 gene, a crucial arsenite [As(III)] antiporter, exhibited increased arsenic tolerance, enabling genetically altered seeds to germinate and flourish under high concentrations of arsenate [As(V)] [57]. Various biotechnology techniques, such as biosorption, phytostabilization, mycoremediation, hyperaccumulation, dendroremediation, biostimulation, cyanoremediation, and genoremediation, depend on boosting or blocking specific gene activity for effective bioremediation [59].

1. **Role of Recombinant DNA technology in Agricultural sector**

The application of recombinant DNA technology has yielded significant advancements in various domains of the food industry and agriculture. One prominent area of progress is the production of specialized enzymes tailored for specific food-processing settings. These enzymes, such as lipases and amylases, play crucial roles in the food industry due to their specialized functions and diverse uses. Additionally, recombinant DNA technology has facilitated the generation of microbial strains capable of manufacturing enzymes, particularly proteases, through targeted engineering. Moreover, modifications in fungal strains have been implemented to reduce their capacity to produce hazardous compounds, enhancing food safety [63].

Among the noteworthy achievements made possible by recombinant DNA technology is the utilization of lysozymes, which serve as highly efficient tools for eliminating microorganisms in the food industry. Lysozymes effectively prevent microbiological organisms from colonizing food products, thereby extending the shelf life of fruits, vegetables, cheese, and meat. The immobilization of lysozymes in polyvinyl alcohol films and cellulose further aids in suppressing food-spoiling germs, enhancing food preservation [64].

In the field of medicine, recombinant proteins have emerged as essential therapeutic agents, with the first plant-based medications recently developed. Various plant species have been engineered to express recombinant proteins with medicinal significance, including proteins found in milk, which are important for nutrition, as well as novel polymeric proteins utilized in industrial and medicinal applications. Notably, the idea of oral vaccination through edible plants has garnered interest, with the successful development of HBV vaccine manufacturing in plants. The production of therapeutic protein products, such as casein and lysozyme, has also been achieved, contributing to the enhancement of child health, tissue replacement, and surgical procedures. Furthermore, genetically modified tobacco plants have been harnessed to produce human collagen, opening new avenues for recombinant protein production [66].

Crop improvement through genetic modification has also been a significant area of focus. The discovery of the PSTOL1 (phosphorus starvation tolerance1) gene in rice has played a crucial role in traditional breeding and quantitative trade locus (QTL) analysis. PSTOL1 enhances root growth, enabling plants to better tolerate phosphorus deficiency and absorb nutrients efficiently, ultimately leading to increased crop output [67]. In addition, research on the chloroplast genome sequences has unveiled the transfer of certain genes, such as Rpl22, from the chloroplast to the nuclear genome. This genetic transfer maintains essential functions like photosynthesis, while some crucial genes have been found to transfer into the nucleus to prevent abnormalities in photosynthesis and other critical processes. The stable integration of transgenes into the chloroplast genome further enhances the potential for successful genetic engineering in plants [68].

Gene expression profiling has emerged as a powerful tool for identifying tissue-specific genes and understanding crop responses to environmental challenges. Employing full-length cDNAs, such as the 44 K Agilent Oligonucleotide microarray for studying the transcriptome of field-grown rice, allows the prediction of changes in gene expression and transcriptome dynamics, aiding in the improvement of crop yield and resilience to environmental and microbial challenges [70].

In summary, recombinant DNA technology has revolutionized various aspects of the food industry and agriculture. From the production of specialized enzymes that enhance food quality and preservation to the development of therapeutic proteins and the engineering of crop traits, this technology has had a profound impact on these fields. However, ethical considerations and potential risks associated with genetic modification must be addressed, ensuring the responsible and safe application of recombinant DNA technology to benefit society as a whole.



**Figure 2**. Application of Recombinant DNA Technology in different sectors.

1. **Challenges in Recombinant DNA technology**

Recombinant DNA technology has revolutionized the production of pharmaceuticals, particularly in microbial cells. However, several challenges hinder the effective manufacturing of functional proteins in these cells. Barriers such as posttranslational modifications, cell stress responses, proteolytic instability, limited solubility, and gene expression resistance need to be addressed. Human genetic mutations can lead to protein production shortages, but the addition of foreign genes can correct these deficiencies and restore normal levels. Escherichia coli serves as a biological framework for recombinant DNA technology, enabling controlled and technically precise generation of necessary molecules [71].

The study of yeast biology has also greatly benefited from recombinant DNA research. Investigating and manipulating yeast genes not only in the test tube but also in living yeast cells has expanded our understanding of yeast biology. DNA transformation and gene cloning are now possible using specially created selectable marker systems, allowing manipulation and analysis of yeast genetic material at both the molecular and traditional genetic levels. This technology has been particularly successful in addressing biological issues related to the structure and organization of individual genes [72].

Furthermore, recombinant DNA technology has opened exciting avenues for exploring biosynthetic pathways through genetic manipulation. Actinomycetes, which are used in pharmaceutical production, have been extensively utilized in the generation of useful chemicals in health sciences. By manipulating biosynthetic pathways, these actinomycetes contribute to the development of innovative medications. Their compounds have shown high efficacy against various bacteria and harmful germs, making them valuable in clinical trials. Additionally, these substances exhibit promising anticancer and immunosuppressive properties [73].

Gene therapy, a revolutionary approach to preventing and treating acquired genetic abnormalities, has also emerged through recombinant DNA technology. DNA vaccines have been developed as a novel method to prevent various diseases by introducing genes that produce specific proteins. In the context of human gene therapy, clinical trials have primarily focused on treating cancer. Researchers are particularly interested in achieving high transfection effectiveness to develop gene delivery systems with minimal side effects for various cancer types, such as brain, breast, lung, and prostate cancers. Additionally, gene therapy is being explored for other conditions, including renal transplantation, Gaucher disease, hemophilia, Alport syndrome, renal fibrosis, and more [74].

Recombinant DNA technology has revolutionized various aspects of pharmaceutical production, yeast biology research, and gene therapy. Overcoming barriers in microbial protein production has opened doors for the development of new pharmaceuticals. The study of yeast genetics has been greatly facilitated by this technology, enhancing our understanding of yeast biology. Moreover, the manipulation of biosynthetic pathways in actinomycetes offers new possibilities for pharmaceutical development. Gene therapy, on the other hand, holds promise for addressing genetic abnormalities and preventing diseases through DNA vaccines. As this technology continues to advance, it is expected to yield further breakthroughs in medical and biological research, significantly impacting human health and disease treatment.

1. **Conclusion**

Recombinant DNA technology has undoubtedly become a driving force in the fields of genetics and molecular biology, revolutionizing scientific research, medical applications, and environmental solutions. Over the years, significant advancements have been made, leading to the creation of a wide range of products for better health, improved agriculture, and environmental sustainability. In this conclusion, we summarize the key contributions and potential implications of recombinant DNA technology and highlight the challenges that still need to be addressed. The advent of recombinant DNA technology in 1973 marked a turning point in biological research, enabling scientists to manipulate genetic information with precision [2]. The ability to insert specific gene sequences from various sources into vectors has unlocked a vast array of possibilities for genetic engineering and product development. From the production of therapeutic proteins, hormones, and antibodies to gene therapy and the creation of genetically modified organisms (GMOs), the applications of recombinant DNA technology have been vast and varied. One of the most significant advancements in the health sector has been in the field of gene therapy. The successful treatment of genetic diseases like ADA-SCID and X-ALD using gene therapy has shown great promise for future medical treatments. Gene therapy has also emerged as a promising approach in cancer treatment, with targeted gene editing and immunotherapies offering new avenues for personalized and effective cancer care. While gene therapy still faces challenges related to delivery methods and off-target effects, ongoing research and improvements in gene editing technologies like CRISPR/Cas9 hold great potential for addressing these limitations [29, 30].

The production of antibodies and their derivatives using recombinant DNA technology has revolutionized disease diagnosis and treatment. Through genetic engineering, scientists can produce specific antibodies that target pathogens and disease markers, leading to more accurate and efficient diagnostic tools and therapeutic agents. These advancements have not only improved the treatment of infectious diseases but also opened up new possibilities for immunotherapy in cancer treatment. The investigation of drug metabolism using recombinant DNA techniques has provided valuable insights into drug interactions and efficacy. By expressing key enzymes involved in drug metabolism, researchers can study how different compounds are processed and metabolized in the body. This knowledge has implications for drug development, personalized medicine, and drug safety assessment. In the field of environmental science, recombinant DNA technology has offered innovative solutions for bioremediation and sustainable energy production. Genetically modified bacteria and plants have been engineered to absorb and break down pollutants, leading to cleaner environments and reduced environmental impact. Moreover, the potential for using cyanobacteria to produce eco-friendly hydrogen as an energy source offers a promising alternative to carbon-based energy sources [64].

Despite the remarkable progress made in recombinant DNA technology, several challenges remain. Ethical considerations surrounding the use of genetically modified organisms, particularly in agriculture, continue to spark debate. The safety and long-term effects of gene therapy and the potential for off-target effects in gene editing also warrant careful assessment and regulation. Furthermore, the economic accessibility of recombinant DNA products in developing countries must be addressed to ensure equitable access to these advancements in healthcare. Thus, recombinant DNA technology has reshaped the landscape of biological research and holds immense potential for improving human health, agriculture, and environmental sustainability. From gene therapy and antibody production to investigating drug metabolism and environmental bioremediation, the applications of this technology are vast and far-reaching. As scientists continue to refine and expand this technology, it is poised to play a central role in shaping the future of various industries and improving human well-being. While challenges remain, continuous research, ethical considerations, and regulatory oversight are essential to harness the full potential of recombinant DNA technology for the benefit of society. Collaborative efforts between scientists, policymakers, and the public will ensure that this powerful tool is used responsibly and ethically to address pressing global challenges and promote a healthier and more sustainable future for all. As we venture into the future, recombinant DNA technology will undoubtedly remain at the forefront of scientific advancements, paving the way for transformative breakthroughs in medicine, agriculture, and environmental conservation.

**References**

[1] A. Berk, S. L. Zipursky, and H. Lodish, "Molecular cell biology 4th edition," National Center for Biotechnology Information's Bookshelf, 2000.

[2] M. Bazan-Peregrino et al., "Combining virotherapy and angiotherapy for the treatment of breast cancer," Cancer gene therapy, vol. 20, no. 8, pp. 461-468, 2013.

[3] M. Venter, "Synthetic promoters: genetic control through cis engineering," Trends in plant science, vol. 12, no. 3, pp. 118-124, 2007.

[4] P. T. Lomedico, "Use of recombinant DNA technology to program eukaryotic cells to synthesize rat proinsulin: a rapid expression assay for cloned genes," Proceedings of the National Academy of Sciences, vol. 79, no. 19, pp. 5798-5802, 1982.

[5] L. X. Li et al., "Antitumor efficacy of a recombinant adenovirus encoding endostatin combined with an E1B55KD-deficient adenovirus in gastric cancer cells," Journal of translational medicine, vol. 11, pp. 1-13, 2013.

[6] C. Méndez and J. A. Salas, "On the generation of novel anticancer drugs by recombinant DNA technology: the use of combinatorial biosynthesis to produce novel drugs," Combinatorial Chemistry & High Throughput Screening, vol. 6, no. 6, pp. 513-526, 2003.

[7] B. C. J. M. Fauser et al., "Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency," Human Reproduction Update, vol. 15, no. 3, pp. 309-321, 2009.

[8] O. W. Merten and B. Gaillet, "Viral vectors for gene therapy and gene modification approaches," Biochemical Engineering Journal, vol. 108, pp. 98-115, 2016.

[9] O. W. Merten et al., "Manufacturing of viral vectors for gene therapy: part I. Upstream processing," Pharm Bioprocess, vol. 2, no. 2, pp. 183-203, 2014.

[10] S. L. Ginn et al., "Gene therapy clinical trials worldwide to 2012–an update," The journal of gene medicine, vol. 15, no. 2, pp. 65-77, 2013.

[11] A. Rivero-Müller, S. Lajić, and I. Huhtaniemi, "Assisted large fragment insertion by Red/ET-recombination (ALFIRE)—an alternative and enhanced method for large fragment recombineering," Nucleic acids research, vol. 35, no. 10, p. e78, 2007.

[12] I. V. Metzger and C. R. Raetz, "Purification and characterization of the lipid A disaccharide synthase (LpxB) from Escherichia coli, a peripheral membrane protein," Biochemistry, vol. 48, no. 48, pp. 11559-11571, 2009.

[13] E. A. Masson et al., "Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog)," Diabetic medicine, vol. 20, no. 1, pp. 46-50, 2003.

[14] A. K. Patra et al., "Optimization of inclusion body solubilization and renaturation of recombinant human growth hormone from Escherichia coli," Protein expression and purification, vol. 18, no. 2, pp. 182-192, 2000.

[15] D. C. Macallan et al., "Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone," HIV clinical trials, vol. 9, no. 4, pp. 254-268, 2008.

[16] E. Pennisi, "The CRISPR craze," Science, vol. 341, no. 6148, pp. 833-836, 2013.

[17] R. Wang et al., "DNA motifs determining the accuracy of repeat duplication during CRISPR adaptation in Haloarcula hispanica," Nucleic acids research, vol. 44, no. 9, pp. 4266-4277, 2016.

[18] S. Shmakov et al., "Discovery and functional characterization of diverse class 2 CRISPR-Cas systems," Molecular cell, vol. 60, no. 3, pp. 385-397, 2015.

[19] G. Gasiunas and V. Siksnys, "RNA-dependent DNA endonuclease Cas9 of the CRISPR system: Holy Grail of genome editing?," Trends in Microbiology, vol. 21, no. 11, pp. 562-567, 2013.

[20] P. Mohanraju et al., "Diverse evolutionary roots and mechanistic variations of the CRISPR-Cas systems," Science, vol. 353, no. 6299, p. aad5147, 2016.

[21] A. P. Hynes, S. J. Labrie, and S. Moineau, "Programming native CRISPR arrays for the generation of targeted immunity," MBio, vol. 7, no. 3, pp. 10-1128, 2016.

[22] F. Hille and E. Charpentier, "CRISPR-Cas: biology, mechanisms and relevance," Philosophical transactions of the royal society B: biological sciences, vol. 371, no. 1707, p. 20150496, 2016.

[23] D. Rath et al., "The CRISPR-Cas immune system: biology, mechanisms and applications," Biochimie, vol. 117, pp. 119-128, 2015.

[24] G. Liu et al., "Diverse CRISPR-Cas responses and dramatic cellular DNA changes and cell death in pKEF9-conjugated Sulfolobus species," Nucleic Acids Research, vol. 44, no. 9, pp. 4233-4242, 2016.

[25] P. R. Blackburn et al., "The CRISPR system—keeping zebrafish gene targeting fresh," Zebrafish, vol. 10, no. 1, pp. 116-118, 2013.

[26] G. D. Yancopoulos, S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash, "Vascular-specific growth factors and blood vessel formation," Nature, vol. 407, no. 6801, pp. 242-248, April 2000.

[27] M. Kamionka, "Engineering of therapeutic proteins production in Escherichia coli," Curr. Pharm. Biotechnol., vol. 12, no. 2, pp. 268-274, 2011.

[28] D. J. Urban and B. L. Roth, "DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility," Annu. Rev. Pharmacol. Toxicol., vol. 55, pp. 399-417, 2015.

[29] S. Hacein-Bey-Abina et al., "Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy," N. Engl. J. Med., vol. 346, no. 16, pp. 1185-1193, April 2002.

[30] S. J. Howe et al., "Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients," J. Clin. Invest., vol. 118, no. 9, 2008.

[31] A. Aiuti et al., "Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement," Nat. Med., vol. 8, no. 5, pp. 423-425, May 2002.

[32] E. Montini et al., "Integration site analysis in a clinical trial of lentiviral vector based hematopoietic stem cell gene therapy for metachromatic leukodystrophy," Hum. Gene Ther., vol. 23, no. 10, pp. A13-A14, October 2012.

[33] R. A. Morgan et al., "Cancer regression in patients after transfer of genetically engineered lymphocytes," Science, vol. 314, no. 5796, pp. 126-129, October 2006.

[34] J. E. Adair et al., "Extended survival of glioblastoma patients after chemoprotective HSC gene therapy," Sci. Transl. Med., vol. 4, no. 133, p. 133ra57, April 2012.

[35] M. G. Ott et al., "Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1," Nat. Med., vol. 12, no. 4, pp. 401-409, April 2006.

[36] S. Stein et al., "Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease," Nat. Med., vol. 16, no. 2, pp. 198-204, February 2010.

[37] P. Lam et al., "The innovative evolution of cancer gene and cellular therapies," Cancer Gene Ther., vol. 20, no. 3, pp. 141-149, March 2013.

[38] N. P. Restifo, M. E. Dudley, and S. A. Rosenberg, "Adoptive immunotherapy for cancer: harnessing the T cell response," Nat. Rev. Immunol., vol. 12, no. 4, pp. 269-281, April 2012.

[39] D. Maddalo et al., "In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system," Nature, vol. 516, no. 7531, pp. 423-427, December 2014.

[40] J. Liu et al., "Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974," Proc. Natl. Acad. Sci. USA, vol. 110, no. 50, pp. 20224-20229, December 2013.

[41] J. H. Kreijtz et al., "A single immunization with modified vaccinia virus ankara–based influenza virus H7 vaccine affords protection in the Influenza A (H7N9) pneumonia ferret model," J. Infect. Dis., vol. 211, no. 5, pp. 791-800, March 2015.

[42] J. D. Smith, "Human Macrophage Genetic Engineering," Arterioscler. Thromb. Vasc. Biol., vol. 36, no. 1, pp. 2-3, January 2016.

[43] C. Vaquero et al., "A carcinoembryonic antigen‐specific diabody produced in tobacco," FASEB J., vol. 16, no. 3, pp. 408-410, March 2002.

[44] C. W. Adams et al., "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab," Cancer Immunol. Immunother., vol. 55, pp. 717-727, 2006.

[45] M. Bendandi et al., "Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma," Ann. Oncol., vol. 21, no. 12, pp. 2420-2427, December 2010.

[46] S. Kathuria et al., "Efficacy of plant-produced recombinant antibodies against HCG," Hum. Reprod., vol. 17, no. 8, pp. 2054-2061, August 2002.

[47] J. K. Nicholson, E. Holmes, and I. D. Wilson, "Gut microorganisms, mammalian metabolism and personalized health care," Nat. Rev. Microbiol., vol. 3, no. 5, pp. 431-438, May 2005.

[48] J. Zhang et al., "Adenovirus-vectored drug–vaccine duo as a potential driver for conferring mass protection against infectious diseases," Expert Rev. Vaccines, vol. 10, no. 11, pp. 1539-1552, November 2011.

[49] M. Assidi et al., "Identification of potential markers of oocyte competence expressed in bovine cumulus cells matured with follicle-stimulating hormone and/or phorbol myristate acetate in vitro," Biol. Reprod., vol. 79, no. 2, pp. 209-222, August 2008.

[50] C. Q. Ling et al., "The roles of traditional Chinese medicine in gene therapy," J. Integr. Med., vol. 12, no. 2, pp. 67-75, March 2014.

[51] L. Mazzoni et al., "The genetic aspects of berries: from field to health," J. Sci. Food Agric., vol. 96, no. 2, pp. 365-371, January 2016.

[52] J. M. H. King et al., "Rapid, sensitive bioluminescent reporter technology for naphthalene exposure and biodegradation," Science, vol. 249, no. 4970, pp. 778-781, August 1990.

[53] J. Chatterjee and E. A. Meighen, "Biotechnological applications of bacterial bioluminescence (lux) genes," Photochem. Photobiol., vol. 62, no. 4, pp. 641-650, October 1995.

[54] K. Matsui et al., "Enhancement of phosphate absorption by garden plants by genetic engineering: a new tool for phytoremediation," BioMed Res. Int., vol. 2013, 2013.

[55] M. Tamura et al., "Regeneration of transformed verbena (Verbena× hybrida) by Agrobacterium tumefaciens," Plant Cell Rep., vol. 21, pp. 459-466, 2003.

[56] J. M. Jez, S. G. Lee, and A. M. Sherp, "The next green movement: plant biology for the environment and sustainability," Science, vol. 353, no. 6305, pp. 1241-1244, September 2016.

[57] R. B. Horsch et al., "A simple and general method for transferring genes into plants," Science, vol. 227, no. 4691, pp. 1229-1231, February 1985.

[58] E. J. Kim et al., "Oligomerization between BSU1 family members potentiates brassinosteroid signaling in Arabidopsis," Mol. Plant, vol. 9, no. 1, pp. 178-181, January 2016.

[59] D. Mani and C. Kumar, "Biotechnological advances in bioremediation of heavy metals contaminated ecosystems: an overview with special reference to phytoremediation," Int. J. Environ. Sci. Technol., vol. 11, pp. 843-872, 2014.

[60] M. W. Ullah et al., "Encapsulated yeast cell-free system: a strategy for cost-effective and sustainable production of bio-ethanol in consecutive batches," Biotechnol. Bioprocess Eng., vol. 20, pp. 561-575, 2015.

[61] P. Savakis and K. J. Hellingwerf, "Engineering cyanobacteria for direct biofuel production from CO2," Curr. Opin. Biotechnol., vol. 33, pp. 8-14, June 2015.

[62] C. Leang et al., "Engineering Geobacter sulfurreducens to produce a highly cohesive conductive matrix with enhanced capacity for current production," Energy Environ. Sci., vol. 6, no. 6, pp. 1901-1908, June 2013.

[63] Z. S. Olempska-Beer et al., "Food-processing enzymes from recombinant microorganisms—a review," Regul. Toxicol. Pharmacol., vol. 45, no. 2, pp. 144-158, August 2006.

[64] B. Thallinger et al., "Antimicrobial enzymes: an emerging strategy to fight microbes and microbial biofilms," Biotechnol. J., vol. 8, no. 1, pp. 97-109, January 2013.

[65] C. E. Torres et al., "Enzymatic treatment for preventing biofilm formation in the paper industry," Appl. Microbiol. Biotechnol., vol. 92, pp. 95-103, 2011.

[66] R. Gamuyao et al., "The protein kinase Pstol1 from traditional rice confers tolerance of phosphorus deficiency," Nature, vol. 488, no. 7412, pp. 535-539, August 2012.

[67] K. Hiruma et al., "Root endophyte Colletotrichum tofieldiae confers plant fitness benefits that are phosphate status dependent," Cell, vol. 165, no. 2, pp. 464-474, April 2016.

[68] H. Daniell et al., "Chloroplast genomes: diversity, evolution, and applications in genetic engineering," Genome Biol., vol. 17, pp. 1-29, August 2016.

[69] W. Apel and R. Bock, "Enhancement of carotenoid biosynthesis in transplastomic tomatoes by induced lycopene-to-provitamin A conversion," Plant Physiol., vol. 151, no. 1, pp. 59-66, January 2010.

[70] Y. Oono et al., "Genome-wide transcriptome analysis reveals that cadmium stress signaling controls the expression of genes in drought stress signal pathways in rice," PLoS One, vol. 9, no. 5, p. e96946, May 2014.

[71] Z. Vajo, J. Fawcett, and W. C. Duckworth, "Recombinant DNA technology in the treatment of diabetes: insulin analogs," Endocr. Rev., vol. 22, no. 5, pp. 706-717, October 2001.

[72] G. M. Walker and M. SCHAECHTER, Encyclopedia of Microbiology, Elsevier, 2009.

[73] C. Méndez et al., "Structure Alteration of Polyketides by Recombinant DNA Technology in Producer Organisms Prospects for the Generation of Novel Pharmaceutical Drugs," Curr. Pharm. Biotechnol., vol. 1, no. 4, pp. 355-395, 2000.

[74] A. Misra, Ed., "Challenges in delivery of therapeutic genomics and proteomics," Elsevier, 2010.